SEATTLE--(BUSINESS WIRE)--Shape Therapeutics Inc. (ShapeTX), a next-generation RNA-targeting gene therapy company, announces today the upcoming company presentation at the J.P. Morgan 39th Annual Healthcare Conference by Francois Vigneault, PhD., President and Chief Executive Officer. The presentation will highlight significant advancements across the ShapeTX technology platforms, including the use of high throughput screening and machine learning to discover RNAfix™ guide-RNAs that enable highly efficient and specific ADAR-mediated RNA editing in Parkinson’s disease. The presentation will also unveil new data from the AAVid™ capsid discovery technology and the discovery of novel CNS-tropic variants from a non-human primate campaign using billions of engineered AAV5 variants.
“RNA is the software of life. We now have next-generation tools to 'debug' the source code of genetic diseases like Parkinson's by targeting RNA directly in the brain. It will be quite exciting to move our RNA editing and tissue-specific AAV delivery technology to the next phase of their development," said Francois Vigneault, PhD., President and CEO.
About Shape Therapeutics Inc
Shape Therapeutics is a biotechnology company developing next-generation gene therapy technologies to treat the world’s most challenging diseases. ShapeTX gene therapy platform comprises RNAskip™, RNAfix™, and RNAswitch™ payload technology, next-generation tissue-specific AAVid™ delivery technology, and SquareBio, a solution to scalable gene therapy manufacturing based on industrialization of human stable cell lines. The power of the ShapeTX resides in its core AI discovery platform, where data drives decisions in building technology today to enable gene therapies of tomorrow. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing life-long cures to patients. Shape Life!